Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Generics
Sonorant debuts as Mallinckrodt spins off generics
by Rick Mullin
May 30, 2019
| A version of this story appeared in
Volume 97, Issue 22
Mallinckrodt plans to spin off its specialty generics and active pharmaceutical ingredient (API) business to shareholders, creating two independent companies: Sonorant Therapeutics, focused on branded pharmaceuticals, and Mallinckrodt, focused on generics and APIs. Sonorant will retain the constipation drug Amitiza, which was originally to go with specialty generics. Mallinckrodt said in December that it was considering separating the generics business.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X